by Richard Daverman, PhD
January 20, 2014 -- TaiGen Biotechnology, a Taiwan biopharma with a Beijing subsidiary, completed a $35.7 million IPO on Taiwan’s GreTai market. The company’s shares rose 6% in the first trading session, giving TaiGen a valuation of $1.1 billion. TaiGen said it would use the capital to advance its discovery and development pipeline. TaiGen has raised a total of $131 million in venture capital since it was founded in 2001. More details....
Stock Symbol: (TWO: 4157)
Help employers find you! Check out all the jobs and post your resume.
